Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 383 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
383 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—including urothelial, triple negative breast, non-small cell lung, esophageal, pancreatic, ovarian, cervical (squamous), head and neck squamous cell, and prostate cancers—who have exhausted standard therapies and have ECOG 0–1. All participants receive intravenous LY4101174, a novel antibody-drug conjugate targeting nectin-4 and delivering a topoisomerase I inhibitor (exatecan).
ClinicalTrials.gov ID: NCT06238479
TrialFetch AI summary: Adults with metastatic or unresectable non-small cell lung cancer refractory to standard therapies, good performance status, and resectable tumor for TIL harvest receive adoptive transfer of autologous "young" tumor-infiltrating lymphocytes following non-myeloablative cyclophosphamide/fludarabine, then either high- or low-dose aldesleukin (IL-2) for immune support. This personalized cellular immunotherapy aims to induce tumor regression by reinfusing ex vivo-expanded lymphocytes reactive to patient-specific tumor antigens.
ClinicalTrials.gov ID: NCT02133196
TrialFetch AI summary: Eligible patients are adults with locally advanced or metastatic non-small cell lung cancer harboring a KRAS G12C mutation and good performance status. The study is evaluating BBO-8520, a first-in-class dual ON/OFF KRAS G12C inhibitor, as monotherapy and in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT06343402
TrialFetch AI summary: Eligible patients are adults with locally advanced or metastatic solid tumors harboring a KRAS G12D mutation, who have progressed on or are intolerant to standard therapies and meet organ function and performance status criteria. The investigational drug TSN1611, an oral small molecule inhibitor targeting both active and inactive forms of KRAS G12D, is administered as monotherapy.
ClinicalTrials.gov ID: NCT06385925
TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic solid tumors (including NSCLC, high-grade serous ovarian carcinoma, and uterine serous carcinoma), ECOG 0-1, and at least one accessible lesion for biopsy. Patients receive BMS-986463, a novel investigational antineoplastic agent with an undisclosed mechanism of action, as monotherapy.
ClinicalTrials.gov ID: NCT06476808
TrialFetch AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (and in some cohorts, HER2) exon 20 insertion mutations who have received prior therapy, treating them with STX-721, an investigational oral irreversible tyrosine kinase inhibitor that selectively targets mutant EGFR and HER2.
ClinicalTrials.gov ID: NCT06043817
TrialFetch AI summary: Adults with advanced solid tumors and good performance status are eligible for this study of BMS-986507, a bispecific EGFR/HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, in combination with either osimertinib or pembrolizumab. Key exclusions include untreated symptomatic CNS metastases, mixed SCLC/NSCLC, and severe infection or cardiac disease.
ClinicalTrials.gov ID: NCT06618287
TrialFetch AI summary: Adult patients with advanced or metastatic solid tumors harboring a KRAS G12D mutation (including pancreatic, colorectal, or NSCLC), ECOG 0-1, and no prior KRAS G12D inhibitor exposure are eligible for treatment with INCB161734, a selective oral KRAS G12D inhibitor, given alone or in combination with standard therapies (e.g., gemcitabine/nab-paclitaxel, mFOLFIRINOX, cetuximab, or retifanlimab).
ClinicalTrials.gov ID: NCT06179160
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors (including IDH-wildtype glioblastoma) harboring MTAP loss who have progressed on standard therapy, and tests TNG456, a selective, brain-penetrant PRMT5 inhibitor, as monotherapy or in combination with abemaciclib (CDK4/6 inhibitor). Eligible patients must have measurable disease, good performance status, and adequate organ function.
ClinicalTrials.gov ID: NCT06810544
TrialFetch AI summary: This trial enrolls adults with advanced, unresectable or metastatic solid tumors harboring any KRAS mutation who have progressed on or declined standard therapies; patients receive ALTA3263, an oral KRAS isoform-selective inhibitor that targets both active and inactive KRAS states and is designed to inhibit over 90% of known KRAS mutations, including G12D, G12V, and G12C. Prior KRAS inhibitor therapy is generally excluded.
ClinicalTrials.gov ID: NCT06835569